Bio-Bridge Science Selected to Participate in Prestigious Study Targeting Health Care Solutions in Emerging Countries

Bio-Bridge Science, Inc. (OTCBB:BGES) announced today
its participation in a study, entitled Private Sector Development in
Developing Countries: Targeting Local Health Needs through Health
Technology, which explores how small to medium enterprises can address
local health needs in Innovating Developing Countries (IDCs) such as
China, India, Brazil and South Africa. Two members of the research
team, Dr. Sarah E. Frew and Dr. Peter A. Singer, visited Bio-Bridge
Science's soon to be finished GMP lab facility and met with senior
management on May 15, 2006 in Beijing.
   As part of the study, Bio-Bridge Science, Inc. will participate in
exploring ways that the domestic private sector can contribute to the
development of health technologies targeted to address local health
needs. The mission of Bio-Bridge Science, Inc. is to develop and
produce new vaccines and drugs to treat human diseases and improve
human health.
   "We are honored to be selected to participate in this study," said
Dr. Liang Qiao, Chief Executive Officer of Bio-Bridge. "The exposure
among many of the key thought and opinion leaders in these countries
will raise our profile in these key markets. As a Company that has
focused on developing cost-effective vaccines for large unmet medical
needs in countries such as China, we believe that we are uniquely
qualified to offer solutions to these challenges."

   About Bio-Bridge Science:

   Bio-Bridge Science is a biotechnology firm focused on the
development of vaccines with broad therapeutic and preventive
applications. Through its wholly owned subsidiary in Beijing,
Bio-Bridge is developing a promising new HIV Vaccine that is expected
to enter clinical trials this year in China. The vaccine, based on
exclusive technology co-developed by CEO Liang Qiao, an associate
professor at Loyola University Chicago's Strich School of Medicine,
targets infection in mucosal tissues, the first type of tissue
attacked by HIV.
   The Chinese government, mindful of the rapid expansion of AIDS in
China has, through the "Green Mile Policy", acted to expedite the
approval of domestically produced HIV Vaccines and has dramatically
increased its spending on AIDS-related research. In accordance with
this policy, Bio-Bridge expects to bring its therapeutic HIV Vaccine
to market as early as late 2008, far in advance of many other HIV
Vaccines currently in development. Bio-Bridge is currently
constructing a new $3 million state-of-the-art GMP research and
manufacturing facility in Beijing, which is expected to be completed
by mid-year. The facility will also be used to develop vaccines
against cervical cancer and colon cancer under the same technology
platform as the HIV vaccine.